Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Vorinostat × Thoracic × Clear all

Phase

Phase 1 14 Phase 1/2 7 Phase 2 4 Phase NA 1 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 3 Plasma cell 2 Dermatologic 2 Thoracic 1 Other solid neoplasm 1 Other hematologic neoplasm 1

Conditions

Mesothelioma 1 Lung Neoplasms 1

Interventions

Carboplatin 246 Cisplatin 196 Pemetrexed 166 Paclitaxel 127 Docetaxel 115 pembrolizumab 92 Gemcitabine 75 Etoposide 57 Erlotinib Hydrochloride 54 Radiotherapy 49 durvalumab 44 Bevacizumab 39 Vinorelbine 38 atezolizumab 36 Gefitinib 36 Nivolumab 35 Drug Therapy 30 osimertinib 25 Topotecan 23 tislelizumab 19 130-nm albumin-bound paclitaxel 19 Radiosurgery 18 Ipilimumab 15 Crizotinib 15 Albumin-Bound Paclitaxel 13 aumolertinib 12 Platinum 12 Magnetic Resonance Spectroscopy 12 Dexamethasone 12 Cyclophosphamide 12

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00128102 2020-10-26

MK-0683-014

Merck Sharp & Dohme LLC

Phase 3 Completed

661 enrolled 18 charts

Other solid neoplasmThoracic

Lung Neoplasms, Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡